Table 3. Complications in-hospital for VIV-TAVI with BVF versus without BVF.
| BVF (N=81) | Control (N=79) | p-value | |
| Device success, % | 93 (75) | 68 (54) | <0.001 |
| Prosthesis failure, %* | 6 (5) | 28 (22) | |
| 2nd valve required, % | 0 (0) | 4 (3) | |
| In-hospital mortality, %+ | 1 (1) | 3 (2) | |
| Ventricular septal rupture, % | 3 (2) | (0) | |
| Aortic root rupture, % | 0 (0) | (0) | |
| All stroke, % | 0 (0) | 3 (2) | |
| Coronary obstruction, % | 0 (0) | 3 (2) | |
| Balloon rupture, % | 0 (0) | (0) | |
| Cardiac tamponade, % | 0 (0) | (0) | |
| Permanent pacemaker, % | 1 (1) | 3 (2) | |
| *due to residual gradient ≥20 mmHg. +BVF: retroperitoneal bleeding after balloon rupture in iliac artery. Control: one patient due to severe cardiomyopathy, one patient due to coronary obstruction at day 3. | |||